rdf:type |
|
lifeskim:mentions |
umls-concept:C0005528,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0035553,
umls-concept:C0038410,
umls-concept:C0205314,
umls-concept:C0597295,
umls-concept:C0679622,
umls-concept:C0912830,
umls-concept:C1167622,
umls-concept:C1449860,
umls-concept:C2603343
|
pubmed:issue |
6
|
pubmed:dateCreated |
2000-7-11
|
pubmed:abstractText |
Macrolide resistance in Streptococcus pneumoniae has been associated with two main mechanisms: target modification by Erm methyltransferases and efflux by macrolide pumps. The ketolide ABT-773, which has a 3-keto group and no L-cladinose sugar, represents a new class of drugs with in vitro activity against a variety of resistant bacteria. Several approaches were undertaken to understand how ABT-773 was able to defeat resistance mechanisms. We demonstrated tighter ribosome binding of ABT-773 than erythromycin. We also showed that ABT-773 (i) accumulated in macrolide-sensitive S. pneumoniae at a higher rate than erythromycin, (ii) was able to bind with methylated ribosomes, though at lower affinities than with wild-type ribosomes, and (iii) accumulated in S. pneumoniae strains with the efflux-resistant phenotype.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-10524961,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-10639382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-2159256,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-2178338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-2506804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-4966821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-7354244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-7793855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-8843287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-8985659,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-8987357,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-9333056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10817709-9736575
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0066-4804
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1562-7
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
|
pubmed:year |
2000
|
pubmed:articleTitle |
Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae.
|
pubmed:affiliation |
Infectious Disease Research, Abbott Laboratories, Abbott Park, Illinois 60064-6217, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|